U.S. markets closed
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • Dow 30

    29,490.89
    +765.38 (+2.66%)
     
  • Nasdaq

    10,815.43
    +239.82 (+2.27%)
     
  • Russell 2000

    1,708.87
    +44.15 (+2.65%)
     
  • Crude Oil

    83.35
    -0.28 (-0.33%)
     
  • Gold

    1,708.30
    +6.30 (+0.37%)
     
  • Silver

    20.77
    +0.18 (+0.88%)
     
  • EUR/USD

    0.9828
    +0.0027 (+0.28%)
     
  • 10-Yr Bond

    3.6510
    -0.1530 (-4.02%)
     
  • GBP/USD

    1.1319
    +0.0153 (+1.37%)
     
  • USD/JPY

    144.5870
    -0.1420 (-0.10%)
     
  • BTC-USD

    19,567.58
    +347.21 (+1.81%)
     
  • CMC Crypto 200

    444.05
    +8.70 (+2.00%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor

·1 min read
  • A major overhang has been lifted with the FDA approval of Revance Therapeutics Inc's (NASDAQ: RVNC) Daxxify (DaxibotulinumtoxinA-lanm).

  • The catalyst also provides a transformative growth driver for Revance in the ~$1.7 billion U.S. cosmetic toxin market.

  • Mizuho has raised the price target to $30 and maintains the Buy rating.

  • "We expect Daxxify to be a major competitor given its best-in-class profile with the 6-month median duration of effect in treating glabellar lines," writes Mizuho analyst.

  • Mizuho estimates Daxxify's price in parity with Botox.

  • HC Wainwright says that the approval didn't come as much of a surprise and raised the price target to $29 with a Buy rating.

  • The big suspense for most investors was whether FDA would grant differentiated labeling in terms of duration because the neuromodulators currently in the market have labeled durations of 3 to 4 months.

  • Including the full dataset will allow its reps to make various claims around durability, which should prove advantageous commercially.

  • Price Action: RVNC shares are up 15% at $29.09 on the last check Friday.

Latest Ratings for RVNC

Date

Firm

Action

From

To

Oct 2021

Barclays

Maintains

Overweight

Oct 2021

Wells Fargo

Downgrades

Overweight

Equal-Weight

Oct 2021

Needham

Maintains

Buy

View More Analyst Ratings for RVNC

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.